Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,MYD.DE,-13000000.0,77052000,23100000,,-49600000,,-39500000,145500000,122800000,-45800000,-45800000,,-3000000,,,,-10100000,173100000,218900000,50300000,-3800000,,-39500000,-39500000,559900000.0,1144500000.0,461700000.0,875200000.0,36500000.0,1336900000.0,800000.0,-266500000.0,109300000.0,328300000.0,-3600000.0,3600000.0,148900000.0,149000000.0,-3600000.0,104000000.0,329200000.0,11900000.0,27200000.0,96500000.0,154000000.0,24600000.0,20800000.0,15300000,-1300000,8200000,-70000000,-48500000,4100000,26500000,31900000,-500000,400000,71800000,18400000,2400000,-4700000,-4500000,2100000,-7100000,180200000.0,en-US,US,EQUITY,False,Delayed Quote,1.2574489,30.6 - 30.6,31.42,30.64,30.22,finmb_31822,XETRA,"Myriad Genetics, Inc.",USD,48,0,20.42,2.005894,10.18 - 30.6,0.0,0.0,10.18,30.6,1620057900,1636378200,1636723800,EUR,REGULAR,30.6,1630567652,0.38000107,30.6,30.6,30.6,100,de_market,2,0,0.20768104,"MYRIAD GENETICS  DL-,01",GER,-0.34,11.411,28.015429,2.5845718,0.0922553,25.337816,5.262184,2381744896,2.681623,15,Europe/Berlin,CEST,7200000,False,False,1.64,,,30.6,10.18,28.02,25.34,48,,77.05M,,75.23M,1.74%,99.19%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-5.01%,-28.87%,,,608.7M,8.08,5.50%,416.8M,-103.6M,-30.5M,-0.34,,176.1M,2.29,217.4M,24.84,2.21,11.41,-92.4M,,Value,84108,Healthcare,2700,4,3,"Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",Salt Lake City,801 584 3600,UT,6,1609372800,1625011200,1,United States,http://myriad.com,86400,3,320 Wakara Way,801 584 3640,Diagnostics & Research
t-1,MYD.DE,-25800000.0,77052000,18200000,,-55700000,,-44200000,132900000,107500000,-43600000,-43600000,,-2900000,,,,-11500000,154600000,198200000,47100000,-12100000,,-44200000,-44200000,576500000.0,1109500000.0,538900000.0,879900000.0,32700000.0,1418800000.0,800000.0,-233300000.0,117600000.0,329200000.0,2900000.0,2300000.0,117000000.0,145900000.0,2900000.0,100400000.0,389400000.0,21000000.0,33700000.0,91500000.0,224800000.0,27100000.0,20500000.0,15300000,0,8200000,-70000000,-48500000,4100000,26500000,31900000,-500000,400000,71800000,18400000,2400000,-4700000,-4500000,2100000,-7100000,243500000.0,en-US,US,EQUITY,False,Delayed Quote,1.2574489,30.6 - 30.6,31.42,30.64,30.22,finmb_31822,XETRA,"Myriad Genetics, Inc.",USD,48,0,20.42,2.005894,10.18 - 30.6,0.0,0.0,10.18,30.6,1620057900,1636378200,1636723800,EUR,REGULAR,30.6,1630567652,0.38000107,30.6,30.6,30.6,100,de_market,2,0,0.20768104,"MYRIAD GENETICS  DL-,01",GER,-0.34,11.411,28.015429,2.5845718,0.0922553,25.337816,5.262184,2381744896,2.681623,15,Europe/Berlin,CEST,7200000,False,False,1.64,,,30.6,10.18,28.02,25.34,48,,77.05M,,75.23M,1.74%,99.19%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-5.01%,-28.87%,,,608.7M,8.08,5.50%,416.8M,-103.6M,-30.5M,-0.34,,176.1M,2.29,217.4M,24.84,2.21,11.41,-92.4M,,Value,84108,Healthcare,2700,4,3,"Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",Salt Lake City,801 584 3600,UT,6,1609372800,1625011200,1,United States,http://myriad.com,86400,3,320 Wakara Way,801 584 3640,Diagnostics & Research
t-2,MYD.DE,-9900000.0,77052000,17600000,,-43700000,,-15200000,124100000,101000000,-40700000,-40700000,,-2900000,,,,-28500000,145200000,185900000,44200000,-3000000,,-15200000,-15200000,590900000.0,1101200000.0,535200000.0,909300000.0,39100000.0,1444500000.0,800000.0,-189100000.0,123400000.0,328300000.0,-3600000.0,1200000.0,118300000.0,133700000.0,-3600000.0,99400000.0,394500000.0,30200000.0,42100000.0,87100000.0,224600000.0,26600000.0,19100000.0,18600000,-3800000,17100000,-70000000,-3900000,-8900000,26500000,-45400000,-3800000,700000,-59300000,17700000,2600000,-17000000,-100000,73200000,-1500000,260800000.0,en-US,US,EQUITY,False,Delayed Quote,1.2574489,30.6 - 30.6,31.42,30.64,30.22,finmb_31822,XETRA,"Myriad Genetics, Inc.",USD,48,0,20.42,2.005894,10.18 - 30.6,0.0,0.0,10.18,30.6,1620057900,1636378200,1636723800,EUR,REGULAR,30.6,1630567652,0.38000107,30.6,30.6,30.6,100,de_market,2,0,0.20768104,"MYRIAD GENETICS  DL-,01",GER,-0.34,11.411,28.015429,2.5845718,0.0922553,25.337816,5.262184,2381744896,2.681623,15,Europe/Berlin,CEST,7200000,False,False,1.64,,,30.6,10.18,28.02,25.34,48,,77.05M,,75.23M,1.74%,99.19%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-5.01%,-28.87%,,,608.7M,8.08,5.50%,416.8M,-103.6M,-30.5M,-0.34,,176.1M,2.29,217.4M,24.84,2.21,11.41,-92.4M,,Value,84108,Healthcare,2700,4,3,"Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",Salt Lake City,801 584 3600,UT,6,1609372800,1625011200,1,United States,http://myriad.com,86400,3,320 Wakara Way,801 584 3640,Diagnostics & Research
t-3,MYD.DE,-14700000.0,77052000,17400000,,-58500000,,-55400000,107400000,56500000,-68300000,-68300000,,-3100000,,,,-3000000,93200000,161500000,36700000,9800000,,-55500000,-55400000,605300000.0,1096600000.0,486400000.0,918200000.0,42000000.0,1404600000.0,700000.0,-173900000.0,58100000.0,327600000.0,-5200000.0,,163700000.0,147000000.0,-5200000.0,103000000.0,331700000.0,37000000.0,54100000.0,71000000.0,224400000.0,29100000.0,21700000.0,12700000,20300000,10300000,-70000000,1000000,15400000,11800000,42700000,-9800000,1400000,30000000,17700000,1600000,34500000,-1000000,-29500000,-2400000,184700000.0,en-US,US,EQUITY,False,Delayed Quote,1.2574489,30.6 - 30.6,31.42,30.64,30.22,finmb_31822,XETRA,"Myriad Genetics, Inc.",USD,48,0,20.42,2.005894,10.18 - 30.6,0.0,0.0,10.18,30.6,1620057900,1636378200,1636723800,EUR,REGULAR,30.6,1630567652,0.38000107,30.6,30.6,30.6,100,de_market,2,0,0.20768104,"MYRIAD GENETICS  DL-,01",GER,-0.34,11.411,28.015429,2.5845718,0.0922553,25.337816,5.262184,2381744896,2.681623,15,Europe/Berlin,CEST,7200000,False,False,1.64,,,30.6,10.18,28.02,25.34,48,,77.05M,,75.23M,1.74%,99.19%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-5.01%,-28.87%,,,608.7M,8.08,5.50%,416.8M,-103.6M,-30.5M,-0.34,,176.1M,2.29,217.4M,24.84,2.21,11.41,-92.4M,,Value,84108,Healthcare,2700,4,3,"Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",Salt Lake City,801 584 3600,UT,6,1609372800,1625011200,1,United States,http://myriad.com,86400,3,320 Wakara Way,801 584 3640,Diagnostics & Research
